US 12,030,951 B2
Anti-OX40 antibody and uses thereof
Yizhen Yang, Shanghai (CN); Yu Cai, Shanghai (CN); Xiong Li, Shanghai (CN); Lei Zhou, Shanghai (CN); Weiguo Qing, Shanghai (CN); and Wei-Guo Su, Shanghai (CN)
Assigned to HUTCHISON MEDIPHARMA LIMITED, Shanghai (CN)
Filed by HUTCHISON MEDIPHARMA LIMITED, Shanghai (CN)
Filed on Aug. 18, 2022, as Appl. No. 17/820,682.
Application 17/820,682 is a continuation of application No. PCT/CN2021/087616, filed on Apr. 16, 2021.
Claims priority of application No. 202010304381.8 (CN), filed on Apr. 17, 2020.
Prior Publication US 2023/0151105 A1, May 18, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61P 17/00 (2006.01); A61P 35/04 (2006.01); A61P 37/02 (2006.01); A61P 37/06 (2006.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 47/6849 (2017.08); A61P 17/00 (2018.01); A61P 35/04 (2018.01); A61P 37/02 (2018.01); A61P 37/06 (2018.01); C12N 15/63 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/71 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 13 Claims
OG exemplary drawing
 
1. An isolated anti-OX40 antibody, comprising
(1) heavy chain complementary determining regions (HCDRs), HCDR1, HCDR2 and HCDR3, wherein the HCDR1 comprises the amino acid sequence as set forth in SEQ ID NO: 11, the HCDR2 comprises the amino acid sequence as set forth in SEQ ID NO: 12, and the HCDR3 comprises the amino acid sequence as set forth in SEQ ID NO: 13;
(2) light chain complementary determining regions (LCDRs), LCDR1, LCDR2 and LCDR3, wherein the LCDR1 comprises the amino acid sequence as set forth in SEQ ID NO: 14, the LCDR2 comprises the amino acid sequence as set forth in SEQ ID NO: 15, and the LCDR3 comprises the amino acid sequence as set forth in SEQ ID NO: 16; and
(3) Fc region variant, which is human IgG1 N297A;
wherein the amino acid residues in the Fc region are numbered in accordance with the EU numbering system.